Mukesh Ambani-owned Reliance Life Sciences' COVID-19 vaccine — here's all we know so far
Reliance Life Scienceshas reportedly approached India’s drug regulator, seeking permission for trials of its vaccine.
- The subject expert committee (SEC) is said to have reviewed its application yesterday and gave its approval.
- Phase-1 of the trial usually lasts for 58 days to determine the highest dose that most patients can tolerate.
AdvertisementIndian pharma firm Reliance Life Sciences on Thursday, August 26, reportedly received regulatory approval to conduct clinical trials of its
The company — run by India’s richest man
The subject expert committee (SEC) is said to have reviewed its application on Thursday and has given its approval.
Reliance Life Sciences aims to obtain reliable information on safety, tolerability, how it reacts with living organisms (pharmacokinetics or PK) and mechanism of action of the drug. The company aims to determine the maximum tolerated dose (MTD) with these trials.
Business Insider has reached out to Reliance Life Sciences seeking more details about their vaccine and Phase-1 trials.
A person aware of the development told the publication that Phase-1 of the trial usually lasts for 58 days to determine the highest dose that most patients can tolerate. The company will be able to conduct phase two or three of the vaccine only after phase one is completed, the person told ET.
The vaccine by Reliance Life Sciences will be a recombinant protein vaccine, similar to the Corbevax vaccine developed by Hyderabad-based Biological E. Biological E is expected to apply for an emergency use authorisation (EUA), which allows temporary use of a medicine under specific conditions.
So far, six vaccines have received EUA in India. This includes Zydus Cadila’s vaccine, Serum Institute of India’s
Drugs Controller General of India (DCGI) had approved Cadila Healthcare’s ZyCoV-D COVID-19 vaccine for emergency use, earlier this week. ZyCoV-D vaccine is also suitable for the younger population above 12 years of age. Adding to it, the vaccine is needle-free unlike other vaccines.
The company plans to manufacture 10-12 crore doses of ZyCoV-D annually and is expected to be made available in September in India.
Infosys, Wipro, Adani Green and other top stocks to watch out for on August 27
Google-backed Dunzo earned nearly ₹600 crore from 8 cities in FY21, CEO says they'll start expanding now
Amazon, Twitter, Hyundai, and Domino’s are buying Indian software fuelling a $75 billion dream chased by top VCs like Sequoia and Tiger Global
Popular on BI
- Silicon Valley needs to stop laying off workers and start firing CEOs
- A laid-off Google engineer describes losing his 'only career' 16 years after starting as an intern
- OpenAI makes a ChatGPT-like tool called Codex that can write software. Here's why Codex won't replace developers and will instead create more demand for their skills.
- OnePlus launches seven new products at its Cloud 11 event—here’s everything about the OnePlus 11, Buds Pro 2, Keyboard 81 Pro and more
- OnePlus 11 vs iQOO 11 – price, specs and features compared
- OnePlus 11 5G review: High on value, low on excitement
- Delhi to Kochi - Indian destinations international travellers are looking for in 2023
- Post pandemic, more organizations are moving towards e-recruitment, says a survey by HirePro